1
|
Zhaogao L, Yaxuan W, Mengwei X, Haiyu L, Lin L, Delin X. Molecular mechanism overview of metabolite biosynthesis in medicinal plants. Plant Physiol Biochem 2023; 204:108125. [PMID: 37883919 DOI: 10.1016/j.plaphy.2023.108125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 09/21/2023] [Accepted: 10/18/2023] [Indexed: 10/28/2023]
Abstract
Medicinal plants are essential and rich resources for plant-based medicines and new drugs. Increasing attentions are paid to the secondary metabolites of medicinal plants due to their unique biological activity, pharmacological action, and high utilization value. However, the development of medicinal plants is constrained by limited natural resources and an unclear understanding of the mechanisms underlying active medicinal ingredients, thereby rendering the utilization and exploration of secondary metabolites more challenging. Besides, with the advancement of research on biosynthesis and molecular metabolism of natural products from medicinal plants, the methods for studying the biological activity and pharmacological effects of these products are constantly evolving. In recent years, significant progress has been made in the biosynthetic pathways and related regulatory genes of secondary metabolites in medicinal plants, which has greatly advanced both basic research and the development of clinical applications for medicinal plants. In this review, we discuss the past two decades of international research on the development of medicinal plant resources, mainly focusing on the biosynthetic pathway of secondary metabolites, intracellular signal transduction processes, multi-omics applications, and the application of gene editing technology in related research progress. We also discuss future development trends to promote the deep mining and development of natural products from medicinal plants, providing a useful reference.
Collapse
Affiliation(s)
- Li Zhaogao
- Department of Cell Biology, Zunyi Medical University, No.6 Xuefuxi Road Xinpu District of Zunyi City, Zunyi, 563099, Guizhou, China.
| | - Wang Yaxuan
- Department of Cell Biology, Zunyi Medical University, No.6 Xuefuxi Road Xinpu District of Zunyi City, Zunyi, 563099, Guizhou, China.
| | - Xu Mengwei
- Department of Cell Biology, Zunyi Medical University, No.6 Xuefuxi Road Xinpu District of Zunyi City, Zunyi, 563099, Guizhou, China; Department of Medical Instrumental Analysis, Zunyi Medical University, No.6 Xuefuxi Road Xinpu District of Zunyi City, Zunyi, 563099, Guizhou, China.
| | - Liu Haiyu
- Department of Cell Biology, Zunyi Medical University, No.6 Xuefuxi Road Xinpu District of Zunyi City, Zunyi, 563099, Guizhou, China; Guizhou Provincial Demonstration Center of Basic Medical Experimental Teaching, Zunyi Medical University, No.6 Xuefuxi Road Xinpu District of Zunyi City, Zunyi, 563099, Guizhou, China.
| | - Li Lin
- Department of Cell Biology, Zunyi Medical University, No.6 Xuefuxi Road Xinpu District of Zunyi City, Zunyi, 563099, Guizhou, China.
| | - Xu Delin
- Department of Medical Instrumental Analysis, Zunyi Medical University, No.6 Xuefuxi Road Xinpu District of Zunyi City, Zunyi, 563099, Guizhou, China; Guizhou Provincial Demonstration Center of Basic Medical Experimental Teaching, Zunyi Medical University, No.6 Xuefuxi Road Xinpu District of Zunyi City, Zunyi, 563099, Guizhou, China.
| |
Collapse
|
2
|
Xiaolei L, Baohong Y, Haipeng R, Shuzhen L, Jianfeng G, Xiangpo P, Haiyu L, Yuan Y, Dejie Z, Jinhong Y, Huanxin W, Wenhui W, Guohua Y. Current evidence on the cytotoxic T-lymphocyte antigen 4 + 49G > A polymorphism and digestive system cancer risks: a meta-analysis involving 11,923 subjects. Meta Gene 2015; 6:105-8. [PMID: 26629416 PMCID: PMC4634354 DOI: 10.1016/j.mgene.2015.09.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Revised: 09/03/2015] [Accepted: 09/22/2015] [Indexed: 11/26/2022] Open
Abstract
Cytotoxic T-lymphocyte antigen (CTLA-4) plays an important role in downregulating T cell activation and proliferation. The CTLA-4 + 49G > A polymorphism is one of the most commonly studied polymorphisms in this gene due to its association with many cancer types, but the association between CTLA-4 + 49G > A polymorphism and digestive system cancer risks remain inconclusive. An updated meta-analysis based on 17 independent case-control studies consisting of 5176 cancer patients and 6747 controls was performed to address this association. Overall, there was no statistically increased risk of digestive system cancers in every genetic comparison. In subgroup analysis, this polymorphism was significantly linked to higher risks for pancreatic cancer (GG vs. AA, OR = 1.976, 95% CI = 1.496-2.611; GA vs. AA, OR = 1.433, 95% CI = 1.093-1.879; GG/GA vs. AA, OR = 1.668, 95% CI = 1.286-2.164; GG vs. GA/AA, OR = 1.502, 95% CI = 1.098-2.054; G vs. A, OR = 1.394, 95% CI = 1.098-1.770). We also observed increased susceptibility of hepatocellular cell carcinoma in homozygote comparison (OR = 1.433, 95% CI = 1.100-1.866) and dominant model (OR = 1.360, 95% CI = 1.059-1.746). According to the source of controls, significant effects were only observed in hospital-based studies (GA/AA vs. GG, OR = 1.257, 95% CI = 1.129-1.399). In the stratified analysis by ethnicity, no significantly increased risks were found in either Asian or Caucasian. Our findings suggest that the CTLA-4 + 49G > A polymorphism may be associated with the risk of pancreatic cancer and hepatocellular cell carcinoma.
Collapse
Affiliation(s)
- Liu Xiaolei
- Wei Fang People's Hospital, Yu He Road 151#, Kui Wen District, Weifang, Shandong, China
| | - Yang Baohong
- Wei Fang People's Hospital, Yu He Road 151#, Kui Wen District, Weifang, Shandong, China
| | - Ren Haipeng
- Wei Fang People's Hospital, Yu He Road 151#, Kui Wen District, Weifang, Shandong, China
| | - Liu Shuzhen
- Wei Fang People's Hospital, Yu He Road 151#, Kui Wen District, Weifang, Shandong, China
| | - Gao Jianfeng
- Wei Fang People's Hospital, Yu He Road 151#, Kui Wen District, Weifang, Shandong, China
| | - Pan Xiangpo
- Wei Fang People's Hospital, Yu He Road 151#, Kui Wen District, Weifang, Shandong, China
| | - Liu Haiyu
- Wei Fang People's Hospital, Yu He Road 151#, Kui Wen District, Weifang, Shandong, China ; Ping Du People's Hospital, Hong Qi Road 15#, Ping Du, Shandong, China
| | - Yu Yuan
- Wei Fang People's Hospital, Yu He Road 151#, Kui Wen District, Weifang, Shandong, China
| | - Zheng Dejie
- Wei Fang People's Hospital, Yu He Road 151#, Kui Wen District, Weifang, Shandong, China
| | - Yang Jinhong
- Wei Fang People's Hospital, Yu He Road 151#, Kui Wen District, Weifang, Shandong, China
| | - Wang Huanxin
- Wei Fang People's Hospital, Yu He Road 151#, Kui Wen District, Weifang, Shandong, China
| | - Wang Wenhui
- Wei Fang People's Hospital, Yu He Road 151#, Kui Wen District, Weifang, Shandong, China
| | - Yu Guohua
- Wei Fang People's Hospital, Yu He Road 151#, Kui Wen District, Weifang, Shandong, China
| |
Collapse
|